Quick - Wegovy Semaglutide Weight Loss | NAD iv Therapy LA

Quick operates as a physician-supervised metabolic wellness clinic in Los Angeles, California, delivering targeted interventions for weight management and cellular health optimization. Under the clinical oversight of OnGo Care, the practice focuses on two primary therapeutic modalities: Wegovy (semaglutide) injection protocols for weight reduction and intravenous NAD+ therapy for mitochondrial function support. The Los Angeles facility serves patients seeking evidence-based pharmacologic weight loss combined with cellular regeneration strategies, offering a structured approach to metabolic health that extends beyond conventional diet-and-exercise models.

The clinic's semaglutide program utilizes Wegovy, a GLP-1 receptor agonist approved for chronic weight management in adults with obesity or overweight conditions accompanied by weight-related comorbidities. Quick's protocol includes systematic dose titration beginning at 0.25 mg weekly, advancing through five escalation phases to a maintenance dose of 2.4 mg weekly based on individual tolerance and response. Patients receive metabolic monitoring throughout treatment, including assessment of glucose regulation, cardiovascular markers, and body composition changes. The program incorporates regular provider check-ins to evaluate gastrointestinal tolerance, adjust dosing schedules, and address potential side effects such as nausea or constipation. Semaglutide works by mimicking incretin hormones that regulate appetite and insulin secretion, creating satiety signals that reduce caloric intake while improving glycemic control in patients with prediabetic or diabetic conditions.

Quick's NAD+ intravenous therapy delivers nicotinamide adenine dinucleotide directly into circulation, bypassing digestive breakdown to achieve higher bioavailability than oral supplementation. NAD+ functions as a critical coenzyme in cellular energy production, DNA repair mechanisms, and sirtuin activation pathways that influence metabolic regulation and aging processes. The clinic administers NAD+ infusions in controlled clinical settings with dosing protocols tailored to individual patient goals, whether targeting energy enhancement, cognitive clarity, or recovery support. Infusion sessions typically span two to four hours depending on dose and patient tolerance, with providers monitoring for flushing, cramping, or other infusion-related reactions. OnGo Care's clinical team adjusts infusion rates and provides supportive measures to optimize patient comfort during treatment sessions.

Patients initiating care at Quick undergo comprehensive intake evaluation including medical history review, current medication assessment, and discussion of weight loss goals or wellness objectives. For semaglutide candidates, providers evaluate contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. The clinic provides injection training for self-administration, teaching proper subcutaneous technique, injection site rotation, and pen device handling. Patients receive ongoing access to clinical support for questions about injection technique, side effect management, or dose adjustments. The Los Angeles location maintains a clinical environment designed for both quick injection visits and extended NAD+ infusion sessions, accommodating varying patient schedules and treatment needs.

Quick differentiates itself through focused service delivery targeting two specific therapeutic interventions rather than attempting comprehensive functional medicine breadth. This specialization allows the clinic to refine protocols, maintain deep expertise in GLP-1 pharmacology and NAD+ administration, and streamline patient experience for those seeking these particular treatments. The OnGo Care clinical model emphasizes accessibility for Los Angeles residents pursuing metabolic optimization, with appointment availability designed to accommodate working professionals. Patients considering semaglutide therapy should understand that results require consistent weekly injections over extended periods, typically showing progressive weight reduction of 10-15% of baseline body weight over 68 weeks in clinical trials, though individual outcomes vary based on adherence, lifestyle factors, and metabolic variables.